Compare ORLA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORLA | APGE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | ORLA | APGE |
|---|---|---|
| Price | $14.49 | $78.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $27.00 | ★ $99.44 |
| AVG Volume (30 Days) | ★ 3.5M | 945.9K |
| Earning Date | 11-11-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2239.45 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $772,153,000.00 | N/A |
| Revenue This Year | $183.80 | N/A |
| Revenue Next Year | $36.88 | N/A |
| P/E Ratio | $89.40 | ★ N/A |
| Revenue Growth | ★ 145.83 | N/A |
| 52 Week Low | $5.25 | $26.20 |
| 52 Week High | $14.65 | $80.99 |
| Indicator | ORLA | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 66.36 | 68.95 |
| Support Level | $11.99 | $73.55 |
| Resistance Level | $14.65 | $80.99 |
| Average True Range (ATR) | 0.71 | 3.42 |
| MACD | 0.08 | -0.36 |
| Stochastic Oscillator | 83.39 | 75.48 |
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.